Clinical Trial Update: Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase Ib/II clinical trial evaluating zanidatamab in combination with tucatinib and chemotherapy for HER2-positive advanced breast cancer; study status is not y…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Chemotherapy (unspecified)
• Tukysa (tucatinib)
• Zanidatamab

Snippet

Sponsor: MedSIR | Conditions: HER 2 Positive Advanced Breast Cancer, Breast Cancer | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING